AgomAb Therapeutics NV
Close on Oct 19, 2026
About AgomAb Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
AgomAb Therapeutics NV is a biotechnology company focused on advancing therapeutic research programs and developing specialized medicinal assets. The enterprise engages in proprietary scientific evaluation, pipeline innovation, and licensing arrangements to target serious medical conditions. Its operations and related transactions primarily interface with clinical collaborators, institutional healthcare entities, and specialized biotechnology partners across the life sciences ecosystem.
The organization conducts operations internationally across Belgium, Spain, and the United States, maintaining corporate subsidiaries such as Agomab Spain SLU and Agomab US Inc. Its infrastructure includes corporate vehicles and operational office facilities positioned to manage cross-border pharmaceutical development activities. AgomAb Therapeutics maintains its principal executive headquarters in Antwerpen, Belgium.
Summary of the business section of AgomAb Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- AgomAb Therapeutics NV
- Founded
- 2017
- Headquarters
- Antwerpen, Belgium
- Address
- Posthoflei 1/6 2600
- Phone
- (323) 302-3530
- Website
- agomab.com
- Employees
- 62, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- C9
- Fiscal year ends
- December 31
- Auditor
- Didier Delanoye, Diegem, Belgium
Stock & identifiers
- Ticker
- AGMB
- Exchange
- Nasdaq
- IPO date
- Feb 6, 2026
- Shares outstanding
- 34M, Dec 31, 2025
- Filer category
- Non-accelerated filer<br>Emerging growth company
- SEC CIK
- 2020932
- CUSIP
- 00860C102
- ISIN
- US00860C1027
- LEI
- 894500APP6UE5N4PKJ68
- EIN
- 00-0000000
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Tim Jasper Knotnerus | Chief Executive Officer, Director | 45,217 |
| der Horst Paul Henryk van | Chief Business Officer | – |
| Ellen Lefever | General Counsel | – |
| Andrea Saez Borderias | Chief Development Officer | – |
| Philippe Constantin Wiesel | Chief Medical Officer | – |
| Pierre Thadee Victor Kemula | Chief Financial Officer | – |
| Marino Garcia | Director | – |
| Naimish Patel | Director | – |
| Weegen Felice Isabel Verduyn-van | Director | – |
| Angelika Martha Jahreis | Director | – |
| Colin Michael Bond | Director | – |
| David R. Epstein | Director | – |
| Ohad Hammer | Director | – |
Corporate history
Events identified from SEC filings
| Date | Event | Details |
|---|---|---|
| Feb 6, 2026 | IPO | Initial public offering priced (424B4 prospectus) |
| Feb 3, 2026 | Listing | Registration of securities on an exchange (Form 8-A) |